Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
GLATT, STEPHEN J.
FARAONE, STEPHEN V.
and
TSUANG, MING T.
2004.
Dr. Glatt and Colleagues Reply.
American Journal of Psychiatry,
Vol. 161,
Issue. 6,
p.
1135.
Matsumoto, Chima
Shinkai, Takahiro
Hori, Hiroko
Ohmori, Osamu
and
Nakamura, Jun
2004.
Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Psychiatry Research,
Vol. 127,
Issue. 1-2,
p.
1.
Müller, D J
Shinkai, T
De Luca, V
and
Kennedy, J L
2004.
Clinical implications of pharmacogenomics for tardive dyskinesia.
The Pharmacogenomics Journal,
Vol. 4,
Issue. 2,
p.
77.
Fan, J B
and
Sklar, P
2005.
Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia.
Molecular Psychiatry,
Vol. 10,
Issue. 10,
p.
928.
Fan, Jin-Bo
Zhang, Chang-Shun
Gu, Niu-Fan
Li, Xing-Wang
Sun, Wei-Wei
Wang, Hong-Yan
Feng, Guo-Yin
St. Clair, David
and
He, Lin
2005.
Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis.
Biological Psychiatry,
Vol. 57,
Issue. 2,
p.
139.
Richardson, Mary Ann
Chao, Helen M.
Read, Laura L.
Clelland, James D.
and
Suckow, Raymond F.
2006.
Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics,
Vol. 141B,
Issue. 2,
p.
195.
Reynolds, Gavin P
Templeman, Lucy A
and
Godlewska, Beata R
2006.
Pharmacogenetics of schizophrenia.
Expert Opinion on Pharmacotherapy,
Vol. 7,
Issue. 11,
p.
1429.
Ragheb, Moataz M
and
Goldberg, Richard J
2006.
Tardive Dyskinesia in Geriatric Patients.
Aging Health,
Vol. 2,
Issue. 5,
p.
833.
Strous, Rael D.
Lapidus, Raya
Viglin, Dina
Kotler, Moshe
and
Lachman, Herbert M.
2006.
Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia.
Neuroscience Letters,
Vol. 393,
Issue. 2-3,
p.
170.
Srivastava, Vibhuti
Varma, Panchami G.
Prasad, Suman
Semwal, Prachi
Nimgaonkar, Vishwajit L.
Lerer, Bernard
Deshpande, Smita N.
and
BK, Thelma
2006.
Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.
Pharmacogenetics and Genomics,
Vol. 16,
Issue. 2,
p.
111.
Boke, Omer
Gunes, Sezgin
Kara, Nurten
Aker, Servet
Sahin, Ahmet Rifat
Basar, Yildiz
and
Bagci, Hasan
2007.
Association of Serotonin 2A Receptor and Lack of Association of CYP1A2 Gene Polymorphism with Tardive Dyskinesia in a Turkish Population.
DNA and Cell Biology,
Vol. 26,
Issue. 8,
p.
527.
Arranz, M J
and
de Leon, J
2007.
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Molecular Psychiatry,
Vol. 12,
Issue. 8,
p.
707.
Numata, S.
Ueno, S.
Iga, J.
Yamauchi, K.
Hongwei, S.
Kinouchi, S.
Shibuya-Tayoshi, S.
Tayoshi, S.
Aki, H.
Sumitani, S.
Itakura, M.
and
Ohmori, T.
2007.
Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia.
Journal of Neural Transmission,
Vol. 114,
Issue. 2,
p.
255.
Bakker, P R
van Harten, P N
and
van Os, J
2008.
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.
Molecular Psychiatry,
Vol. 13,
Issue. 5,
p.
544.
Lafuente, Amalia
Bernardo, Miquel
Mas, Sergi
Crescenti, Anna
Aparici, Monica
Gasso, Patricia
Deulofeu, Ramon
Mane, Anna
Catalan, Rosa
and
Carne, Xavier
2008.
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Psychiatry Research,
Vol. 161,
Issue. 2,
p.
131.
Dolžan, Vita
Serretti, Alessandro
Mandelli, Laura
Koprivšek, Jure
Kastelic, Matej
and
Plesničar, Blanka Kores
2008.
Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 32,
Issue. 6,
p.
1562.
Wilffert, B
Al Hadithy, AFY
Sing, VJ
Matroos, G
Hoek, HW
van Os, J
Bruggeman, R
Brouwers, JRBJ
and
van Harten, PN
2009.
The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment.
Journal of Psychopharmacology,
Vol. 23,
Issue. 6,
p.
652.
Okochi, Tomo
Ikeda, Masashi
Kishi, Taro
Kawashima, Kunihiro
Kinoshita, Yoko
Kitajima, Tsuyoshi
Yamanouchi, Yoshio
Tomita, Makoto
Inada, Toshiya
Ozaki, Norio
and
Iwata, Nakao
2009.
Meta-analysis of association between genetic variants in COMT and schizophrenia: An update.
Schizophrenia Research,
Vol. 110,
Issue. 1-3,
p.
140.
Al-Janabi, Ismail
Arranz, Maria J.
Blakemore, Alexandra I.F.
Saiz, Pilar A.
Susce, Margaret T.
Glaser, Paul E.A.
Clark, Daniel
and
de Leon, Jose
2009.
Association study of serotonergic gene variants with antipsychotic-induced adverse reactions.
Psychiatric Genetics,
Vol. 19,
Issue. 6,
p.
305.
Zandi, Peter P.
and
Judy, Jennifer T.
2010.
The Promise and Reality of Pharmacogenetics in Psychiatry.
Clinics in Laboratory Medicine,
Vol. 30,
Issue. 4,
p.
931.
Comments
No Comments have been published for this article.